Propanc Health Group Corp (OTCMKTS:PPCH) has announced the signing of Maxim Group as the company’s new strategy advisor. As per the news from the company, Maxim will provide investment banking and corporate planning services to PPCH, to enhance the company’s share value. The main area of focus for the partnership would be PPCH’s investment management, which could finally get PPCH operating on a national level stock exchange.
Propanc Health is focused on the development of collateral and pancreatic cancers. The company’s business model and products make it capable of recording strong performances, equivalent to companies on the NASDAQ listings. All the company needs to do is bring a complete and clinically tested drug to the market. Even SeeThruEquity’s research stated a closing price of $1.52 for PPCH, which is a lot more than the current stock price.
The main reason behind so much support for Propanc is the fact that the PPCH only concentrates on cancers with limited options. It would thus have a very large share in the market. As the company’s lead PRP drug nears the end of clinical trials, PPCH is now looking for licensing partners to help with the commercialization process. The senior management at PPCH believes that Maxim can help the company achieve their goals of quickly moving to a national exchange.
Propanc CEO, James Nathanielsz, stated the long-term growth is one of the main targets of the company and Maxim, with all its experience, can help PPCH achieve that goal. The management at Maxim also revealed that they were delighted on accepting the position at the company, since Maxim sees PPCH as one of the leaders in the Biotech industry. Maxim also stated that it intends to utilize its skilled and experienced staff to ensure that long-term and short-term goals are met quickly and efficiently.
Roth Capital analyst Elemer Piros offered commentary on Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) following the licensing of a program to treat a wide variety of rare blood disorders, including Fanconi Anemia. The analyst maintained a Buy rating on the stock with a price target of $16.00, which represents a potential upside of 126% from where the stock is currently trading.
Piros noted, “We arrive at our 12-month price target of $16/share by adding the after-tax, risk-adjusted NPV of future cash flows from PlasmaTech’s Sanfilippo program combined with a technology value for its additional assets. We currently ascribe a 35% probability of success for the treatment of Sanfilippo syndrome. The probability-adjusted (35%), fully taxed (35%) NPV (15% discount rate) of future cash flows is over $300MM ($11/share), in our calculation.”
started when it was $6.60. now gained $1.00 at this writing.
and it's up trend volume.
What does it tell you?
I am watching the pre-market chart since 7:00 AM, looks like some positive activities are going on different from last couple of days. We may see some margin selling by the opening. If it is a short squeeze then it may neutralize and surpass the selling. TD Ameritrade do its margin selling usually in the late afternoon but I think others do it in the the early hours. A real squeeze make take us close to $15. Any thought?